A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells.
暂无分享,去创建一个
H. Lane | S. Koletar | C. Yoshizawa | L. Saravolatz | N. Markowitz | G. Fyfe | A. Duliege | R. Mitsuyasu | H. Donabedian | A. W. de Boer